

Original Paper

Nationwide Implementation of Unguided Cognitive Behavioral Therapy for Adolescent Depression: Observational Study of SPARX

Terry Fleming^{1,2}, PhD; Mathijs Lucassen³, PhD; Chris Frampton⁴, PhD; Varsha Parag⁵, MSci; Chris Bullen⁶, PhD; Sally Merry⁷, MD; Matthew Shepherd⁸, DClinPsych; Karolina Stasiak⁷, PhD

¹Te Kura Tātai Hauora School of Health, Victoria University of Wellington, Wellington, New Zealand

²Department of Epidemiology and Biostatistics, The University of Auckland, Auckland, New Zealand

³School of Health and Psychological Sciences, City St George's, University of London, London, United Kingdom

⁴Psychological Medicine, University of Otago, Christchurch, New Zealand

⁵National Institute for Health Innovation (NIHI), The University of Auckland, Auckland, New Zealand

⁶School of Population Health, The University of Auckland, Auckland, New Zealand

⁷Department of Psychological of Medicine, The University of Auckland, Auckland, New Zealand

⁸School of Psychology, Massey University, Auckland, New Zealand

Corresponding Author:

Terry Fleming, PhD

Te Kura Tātai Hauora School of Health, Victoria University of Wellington

PO Box 600

Wellington 6140

New Zealand

Phone: 64 7961680776

Fax: 64 800 04 04 04

Email: terry.fleming@vuw.ac.nz

Abstract

Background: Internet-based cognitive behavioral therapy (iCBT) interventions are effective in clinical trials; however, iCBT implementation data are seldom reported.

Objective: The objective of this study is to evaluate uptake, adherence, and changes in symptoms of depression for 12- to 19-year-olds using an unguided pure self-help iCBT intervention (SPARX; Smart, Positive, Active, Realistic, X-factor thoughts) during the first 7 years of it being publicly available without referral in Aotearoa New Zealand.

Methods: SPARX is a 7-module, self-help intervention designed for adolescents with mild to moderate depression. It is freely accessible to anyone with a New Zealand Internet Protocol address, without the need for a referral, and is delivered in an unguided “serious game” format. The New Zealand implementation of SPARX includes 1 symptom measure—the Patient Health Questionnaire adapted for Adolescents (PHQ-A)—which is embedded at the start of modules 1, 4, and 7. We report on uptake, the number of modules completed, and changes in depressive symptoms as measured by the PHQ-A.

Results: In total, 21,320 adolescents aged 12 to 19 years (approximately 2% of New Zealand 12- to 19-year-olds) registered to use SPARX. Of these, 63.6% (n=13,564; comprising n=8499, 62.7% female, n=4265, 31.4% male, and n=800, 5.9% another gender identity or gender not specified; n=8741, 64.4% New Zealand European, n=1941, 14.3% Māori, n=1202, 8.9% Asian, n=538, 4.0% Pacific, and n=1142, 8.4% another ethnic identity; mean age 14.9, SD 1.9 years) started SPARX. The mean PHQ-A at baseline was 13.6 (SD 7.7) with 16.1% (n=1980) reporting no or minimal symptoms, 37.4% (n=4609) reporting mild to moderate symptoms (ie, the target group) and 46.7% (n=5742) reporting moderately severe or severe symptoms. Among those who started, 51.1% (n=6927) completed module 1, 7.4% (n=997) completed at least 4 modules, and 3.1% (n=416) completed all 7 modules. The severity of symptoms reduced from baseline to modules 4 and 7. Mean PHQ-A scores for baseline, module 4, and module 7 for those who completed 2 or more assessments were 14.0 (SD 7.0), 11.8 (SD 7.9), and 10.5 (SD 8.5), respectively; mean difference for modules 1-4 was 2.2 (SD 5.7; $P<.001$) and for modules 1-7 was 3.6 (SD 7.0; $P<.001$). Corresponding effect sizes were 0.38 (modules 1-4) and 0.51 (modules 1-7).

Conclusions: SPARX reached a meaningful proportion of the adolescent population. The effect size for those who engaged with it was comparable to trial results. However, completion was low. Key challenges included logistical barriers such as slow

download speeds and compatibility with some devices. Ongoing attention to rapidly evolving technologies and engagement with them are required. Real-world implementation analyses offer important insights for understanding and improving the impact of evidence-based digital tools and should be routinely reported.

J Med Internet Res 2025;27:e66047; doi: [10.2196/66047](https://doi.org/10.2196/66047)

Keywords: therapy; digital health; serious games; self-help; implementation; cognitive behavioral therapy; CBT; internet-based cognitive behavioral therapy; iCBT; depression; teenager; youth; adolescent; SPARX; mHealth; mobile health

Introduction

Adolescent depression is common and disabling [1,2]. Over 20% of Aotearoa New Zealand secondary school adolescents reported clinically significant depression symptoms in 2019 [3]. Evidence-based talking therapies, including cognitive behavioral therapy (CBT), are the recommended first line of treatment for mild to moderate depression [4]. However, 50%-80% of young people with symptoms do not get treatment [5]. Internet-based cognitive behavioral therapy (iCBT) programs have been developed, partly in response to these challenges, and have been shown to be effective for the treatment of adult and adolescent depression [6].

Co-authors (TF, KS, ML, MS, and SM) developed a computerized CBT intervention for adolescent depression called “SPARX” (Smart, Positive, Active, Realistic, X-factor thoughts). SPARX performed at least as well as treatment as usual in a non-inferiority randomized controlled trial (RCT) with 187 adolescents seeking help for low mood or depression in primary care [7], and it was at least as effective for indigenous Māori adolescents as for non-Māori [8]. In smaller trials, SPARX was effective compared to waitlist control among adolescents excluded from mainstream education [9]; promising in an adapted “Rainbow version” open trial among sexual and gender minority youth [10]; and appealing to a range of youth [11-13], although a Dutch version of SPARX was not more effective than a monitoring control or group-based CBT in an RCT in classroom settings [14]. A revised version of SPARX (SPARX-R), adjusted to include those without depression, was not successfully implemented in a youth justice setting, where participants did not attend the youth justice program regularly and few tried SPARX-R [15]; however, it was effective for the prevention of depression at 6 months follow-up in a large RCT (n=540) conducted in Australian secondary schools [16].

In 2014, the New Zealand Ministry of Health funded SPARX as an unguided self-help iCBT intervention. It was targeted to adolescents with mild to moderate depression but was freely available to anyone with a New Zealand Internet Protocol (IP) address with no referral required. In this paper, we explore outcomes for 12- to 19-year-olds who registered for SPARX from 2014 to 2021; the first 7 years of SPARX being nationally available. There are some complexities. SPARX was originally trialed on CD-ROMs; rapid transition to web-based delivery was required for national rollout. For the first years of national delivery, SPARX was only available via desktop or laptop computers (not smartphones or tablets), so users could register but not begin on a mobile device, and users were required to download a large file, which was not

possible for some (eg, due to firewalls or problematic internet speeds).

Despite, and in part *because* of, operational challenges, it is valuable to examine implementation findings. While there are many trials of evidence-based iCBT programs in the peer-reviewed literature, there are few studies of how these programs perform in real-world settings [17,18]. In a 2018 systematic review, there were peer-reviewed findings from just 7 self-help interventions for depression, anxiety, or enhancement of mood as implemented in real-world settings [17], with these reporting much lower rates of retention than in trials of the same interventions. Moreover, routinely collected internet traffic data indicates median retention in publicly available mental health app-based programs is less than a quarter of that for the same programs evaluated in trials [18]. While there may be user benefits from even brief engagement [18], and, if initial uptake is high, even low rates of completion can have population impact, these data call for examination.

The research-to-implementation distinction is not unique to digital tools. For example, while 6 or more sessions of face-to-face CBT are recommended for initial treatment in many clinical guidelines [4], in practice, there are considerable barriers, including a lack of services, limited resources, and extensive waiting lists [19]. Internet-based interventions offer the ability to examine distinctions between ideal and real implementation, given the opportunities afforded by routine data collection in web-based delivery. In this paper, we report on the uptake, engagement, and impact of SPARX by 12- to 19-year-olds in its implementation in the “real world” as a pure self-help (ie, unguided) intervention.

Methods

Study Design

This was a purely observational retrospective cohort study of national implementation of SPARX iCBT in Aotearoa New Zealand. There were no recruitment or study procedures beyond analysis of anonymous self-reported data and automatically collected analytics for 12- to 19-year-old users who registered to use SPARX via the New Zealand website between April 1, 2014, and September 30, 2021. There were no data collected outside of the SPARX program.

Ethical Considerations

All users, including minors, provided their own consent to use SPARX and for anonymous data to be analyzed for evaluating and improving the program. Synchronous human-delivered support via toll-free telephone, text, or messaging

services was available free of charge. Participants did not receive compensation or payments.

Parent or guardian consent was not required for the use of SPARX as implemented in New Zealand. This decision was made by the funder (the New Zealand Ministry of Health) and provider (the New Zealand Institute of Health Innovation at the University of Auckland) in collaboration with national clinical and governance groups overseeing the SPARX rollout. The decision to allow minors to self-consent was grounded in clinical and ethical considerations. The risks associated with untreated depression and other mental health issues in young people are well documented [1] and parent engagement is a significant barrier to treatment for some [20,21]. Recent New Zealand data underscore this point. Among male secondary school students who had attempted suicide in the past 12 months, only 36% had talked to a parent or family member about feeling bad [22]. Upon registration for SPARX, users agreed to “get extra help” if SPARX was not helping or was not sufficient for their needs. The website and SPARX program included messaging encouraging young people to talk with family members and others, along with guidance on how to do so and where and how to access further support.

Parental or guardian consent was also not required for data to be used in this analysis. Requiring additional consent for the use of routinely collected data can introduce selection bias in observational studies [23] and the New Zealand National Ethical Standards for Health and Disability Research and Quality Improvement [24] and Health Information Governance Guidelines [25] allow for the use of nonidentifiable health information such as this for research and evaluation purposes.

The study was approved by the New Zealand Health and Disability Ethics Committee (reference: 15/NTB/183) and is reported using STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) criteria [26].

Participants and Setting

Automatically collected analytics from all 12- to 19-year-olds who registered for SPARX as implemented between April 1, 2014, and September 30, 2021, were analyzed. There were no exclusion criteria beyond age group, registration, and time period. Given the observational nature of this research, no predetermined sample size was calculated. Instead, the size of the study was based on the number of adolescent users accessing SPARX from the start of the New Zealand-wide rollout of the program (April 1, 2014), to just prior to the use of SPARX 2.0 (ie, a new iteration of the intervention, September 30, 2021).

Participants could register for SPARX on any device with internet access and could open SPARX on a PC or laptop, or, from 2018, on a mobile device from any location via a New Zealand IP address. While there were barriers such as internet firewalls and download speeds (described under “Implementation Model”), the SPARX website was available more than 99.9% of the time, and users could register and begin SPARX at any time during the 7-year study period. Exposure varied

from registration only to completion of all 7 levels of SPARX with no limitations on time taken.

Intervention

The SPARX program has been described elsewhere [7]. In brief, it is a structured iCBT program that includes interpersonal skills and emotion regulation content. SPARX uses a bi-centric frame of reference involving both explicit information giving and discovery or implicit learning [7]. A guide (virtual therapist) introduces the program and “speaks” directly with the user at the start and close of each of the 7 modules, with scripted dialogue to support rapport, hope, engagement, consolidation, and generalization of therapeutic content. The core part of each module takes place in a game-like setting, where the user takes on challenges and solves problems to “restore the balance” and solve problems in a fantasy world, allowing them to discover and rehearse CBT concepts and skills in a playful way as they progress. At the end of each module, users return to the guide to consolidate and review key concepts and to encourage the application of concepts and skills in everyday life with quizzes, open text questions, and reflective exercises.

The therapeutic content of SPARX has also been described previously [7]. In summary, module 1 focuses on building virtual rapport, with caring and welcoming words from the guide and the expression of hope and expectations of improvement (even if multiple steps are required). Psychoeducation about variation in mood and depression and how moods and feelings change is provided. Module 1 also includes how to find additional forms of support, and it introduces relaxation breathing. Module 2 pertains to behavioral activation and key prosocial communication skills. Module 3 focuses on dealing with strong emotions, while module 4 explores problem-solving. Modules 5 and 6 relate to recognizing and challenging unhelpful thoughts and growing realistic positive thoughts and action thinking. Finally, module 7 integrates the included skills and concepts and includes additional strategies and resources for managing persistent challenges.

Implementation Model

In 2014, the SPARX research team, in collaboration with the National Institute for Health Innovation at the University of Auckland, was the successful applicant for New Zealand Ministry of Health funding to deliver a youth e-therapy. A pure self-help delivery model, via a publicly available website with phone or text or web chat support through existing independent agencies, was developed in collaboration with government agencies and advisors. Governance and clinical oversight committees and processes were established. The SPARX program was rapidly adjusted from the CD-ROM version used in the initial RCT for web-based delivery with minor adaptations as outlined in [Textbox 1](#). Promotion was undertaken, including presentations at meetings of health professionals and school staff and via social media advertising targeting young people. Potential users visit the website, which includes access to SPARX and an optional anonymous web-based Patient Health Questionnaire adapted for Adolescents (PHQ-A) [27] assessment, which is presented

as a “Mood Quiz,” to help users identify whether SPARX might help them. Those whose score on this optional measure indicates no or minimal symptoms are encouraged to try SPARX to develop skills for any future challenges; those who score in the mild to moderate range are advised that SPARX may be a helpful tool for them; and those who score in the moderately severe or more severe range or who indicate a risk of self-harm are advised to seek further support and try SPARX once they are safe. Those who wish to access SPARX (with or without completing the “mood quiz” first and regardless of “mood quiz” results) must register by entering an email address, creating a username and password, and answering brief demographic questions. They may opt to get automatic reminders by text or email

and must agree to the terms of use. Once registered, users may begin the program on a PC or laptop, or, from 2018, on a mobile device. As users begin the first module of SPARX, they complete the first in-program PHQ-A and then progress through SPARX modules in the prescribed order at their own pace. In module 1, users are welcomed to the program, advised to complete 1-2 modules per week, and provided information on where to get extra help. Automatic email reminders are sent 2 and 4 weeks after the last use of SPARX for those who opted in for reminders and who had not completed the program. The following key changes were made to SPARX from the research version delivered by CD-ROM in the 2012 RCT [7], for the national implementation of the program ([Textbox 1](#)).

Textbox 1. Changes to SPARX (Smart, Positive, Active, Realistic, X-factor thoughts) for national web-based implementation.

- A Likert scale for rating mood in all modules in the research version was replaced with the Patient Health Questionnaire Adapted for Adolescents (PHQ-A) toward the beginning of modules 1, 4, and 7.
- A list of helping resources and prompts for how and where to seek help was provided on the SPARX website.
- Further messages to prompt help-seeking were added for those with high or deteriorating scores on PHQ-A or item 9 (indicative of a risk of self-harm) within SPARX.
- A dedicated free phone and text number for SPARX users was established. This was supported by a partner telephone and text counseling organization to provide a full-time backup crisis service. Since 2017, users can also request chat-based support via the SPARX website (this is also provided by the partner agency).
- A summary screen for each module was added. This can be printed out and replaces a paper notebook provided with each CD-ROM in the initial SPARX trials.

There were logistical challenges in the first years of implementation, and technical updates were made over this time period. Initially, users were required to download a large file to a computer (not a mobile device); these files were blocked by some firewalls, and downloads were very slow in some settings. Changes in the interface between internet browsers and “Unity Player” (ie, the game platform used for SPARX) meant that only some internet browsers could be used in some time periods. Hence, some registrants could not begin SPARX. A version which could be played on mobile was first available in 2018; however, it appeared as designed for computers and was hard to read and manipulate on mobile devices. A significant update, SPARX (version 2.0), optimized for mobile use, became available after this study period in October 2021. Future analyses will compare SPARX (version 2.0) to data reported here.

Variables

Study variables were collected from routinely gathered user data and automatically collected analytics. User data requirements had been established with the Ministry of Health in order to allow service evaluation while minimizing barriers to engaging with SPARX. These were self-reported demographics (age, gender, ethnicity, and New Zealand region) and how registrants found out about SPARX (eg, school or health professional), all entered by the user on registration, and the adolescent-modified Patient Health Questionnaire 9-item depression scale (PHQ-A) [27], embedded at the beginning of modules 1, 4, and 7 only. There were no symptom measures in other modules, as youth consultation had indicated potential negative impacts of repeated measures on engagement. The PHQ-A is a robust tool for depression

screening [27]. Response options range from never to nearly every day (scores of 0-3) and although not a diagnostic test per se, the total scores can be grouped into 5 symptom levels: none (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), and severe (20-27). We report demographic data with gender categorized as female, male, or transgender or intersex or gender not specified; ethnicity categorized using the New Zealand census ethnicity prioritization method; and age categorized into 12-15 and 16-19 years. Automatically collected analytics are registrations (registering or signing up for SPARX), opening of the SPARX program (ie, “starting,” or opening the program at least once, for any length of time), start and finish times for each module, and number of modules completed. Our primary outcome variable was PHQ-A score.

Statistical Analyses

Summaries of continuous variables have been presented as means and standard deviations or medians and interquartiles for skewed data, while categorical variables have been presented as frequencies and percentages. The extent of the skewness was quantified using Pearson’s coefficient of skewness ($3 \times (\text{mean} - \text{median}) / \text{SD}$). We interpreted values >0.5 as indicating strong positive skewness. For users who completed at least 2 of the 3 PHQ-A scores, the mean changes in PHQ-A scores from baseline (module 1) to module 4, module 7, and the last available module (4 or 7) were analyzed using paired sample *t* tests. The data were treated as normally distributed due to the number of users included in the analyses [28]. Effect size was calculated by dividing the mean difference by the standard deviation of the difference (Cohen *d* for paired samples *t* test). Data were analyzed with

Statistical Package for the Social Sciences (SPSS; version 28.0) and the Statistical Analysis System (SAS; version 9.4).

Results

Between April 2014 and September 2021, 21,310 adolescents aged 12 to 19 years registered for SPARX. As shown in Table 1, the majority (n=13,593, 63.8%) were female. Registrants could select as many ethnic identities as applied to them, with one ethnicity assigned for the purposes of analysis using the New Zealand census ethnicity prioritization method [29]; 15.7% (n=3354) were Indigenous Māori, 4.6% (n=985) identified as Pacific, 8.4% (n=1799) as Asian, 62.8% (n=13,376) were New Zealand European; and 8.4% (n=1796) were of another ethnicity. Two-thirds (n=14,297, 67.1%)

were 12-15 years of age. In total, 13,564 (63.7% of registrants) started SPARX (“starters”). There were significant differences in gender, ethnicity, age, and referral source for starters compared to registrants, with female, Māori, younger, and school-referred participants forming lower proportions of starters than they did of registrants (Table 1). The mean PHQ-A at the start of the program (beginning of module 1) was 13.5 (SD 7.7), with 37.4% (n=4609) reporting mild or moderate symptoms (the target group), 46.7% (n=5742) reporting more severe symptoms, and 16.1% (n=1980) reporting no to minimal symptoms, as shown in Table 1. School was the largest single point of referral to SPARX, with 32.0% (n=4340) of those who started and a professional (ie, counselor, doctor, or nurse) referral was second, with 29.8% (n=4047).

Table 1. Characteristics of 12- to 19-year-olds registering for and starting SPARX (Smart, Positive, Active, Realistic, X-factor thoughts).

| | Total Registrations | Started SPARX | | Difference <i>P</i> value |
|---|---------------------|---------------|-------------|---------------------------|
| | | Yes | No | |
| Total, n | 21,310 | 13,564 | 7746 | — ^a |
| Gender, n (%) | | | | <.001 |
| Female | 13,593 (63.8) | 8499 (62.7) | 5094 (65.8) | |
| Male | 6507 (30.5) | 4265 (31.4) | 2242 (28.9) | |
| Transgender or intersex or gender not specified | 1210 (5.7) | 800 (5.9) | 410 (5.3) | |
| Prioritized ethnicity, n (%) | | | | <.001 |
| Māori | 3354 (15.7) | 1941 (14.3) | 1413 (18.2) | |
| Pacific | 985 (4.6) | 538 (4.0) | 447 (5.8) | |
| Asian | 1799 (8.4) | 1202 (8.9) | 597 (7.7) | |
| Other | 1796 (8.4) | 1142 (8.4) | 654 (8.4) | |
| New Zealand European | 13,376 (62.8) | 8741 (64.4) | 4635 (59.8) | |
| Age | | | | <.001 |
| 12-15 years, n (%) | 14,297 (67.1) | 8908 (65.7) | 5389 (69.6) | |
| 16-19 years, n (%) | 7013 (32.9) | 4656 (34.3) | 2357 (30.4) | |
| Mean (SD) | 14.8 (1.9) | 14.9 (1.9) | 14.6 (1.9) | <.001 |
| Referral source, n (%) | | | | <.001 |
| School | 7136 (33.5) | 4340 (32.0) | 2796 (36.1) | |
| Counselor, doctor, or nurse | 5924 (27.8) | 4047 (29.8) | 1877 (24.2) | |
| Friend | 1370 (6.4) | 887 (6.5) | 483 (6.2) | |
| Google, Facebook, or advertisement | 3090 (14.5) | 1842 (13.6) | 1248 (16.1) | |
| Other | 3790 (17.8) | 2448 (18) | 1342 (17.3) | |
| Baseline PHQ-A ^b , n (%) | | | | — |
| Did not complete | — | 1248 (9.2) | — | |
| Not depressed (0-4) | — | 1980 (16.1) | — | |
| Mild (5-9) | — | 2061 (16.7) | — | |
| Moderate (10-14) | — | 2548 (20.7) | — | |
| Moderately severe (15-19) | — | 2523 (20.5) | — | |
| Severe (20-27) | — | 3219 (26.1) | — | |

^aNot applicable.

^bPHQ-A: Patient Health Questionnaire adapted for Adolescents.

Of those who began SPARX (“starters”; n=13,564), 51.1% (n=6927) completed module 1; 20.9% (n=2841) and 11.3%

(n=1539) completed modules 2 and 3, respectively; 7.4% (n=997) completed module 4 and 3.1% (n=416) finished all

7 modules, as shown in Figure 1. These data represent a 41.0%-77.3% retention at each module (also shown in Figure 1). Users spent a median time of 19 minutes per module, with an interquartile range of 15-25 minutes. Among those

who started the last module and have the module start time available ($n=435$), the median completion time was 12 days, with a wide interquartile range of 2-42 days (Figure 1).

Figure 1. Engagement, April 2014 to September 2021. SPARX: Smart, Positive, Active, Realistic, X-factor thoughts; PHQ-A: Patient Health Questionnaire adapted for Adolescents.




Table 2 provides the mean PHQ-A scores for modules 1, 4, and 7 and paired difference means. Paired t tests show significant reductions in PHQ-A scores between module 1 and module 4 and between module 1 and module 7, as well as module 1 to the last available measure (module 4 or 7), with

$P<.001$ for each of these. Effect sizes (Cohen d) were 0.38 for those who completed the second PHQ-A only (at module 4); 0.51 for those who completed the PHQ-A at module 7; and 0.43 for baseline to last available score (module 4 or 7).

Table 2. PHQ-A^a score at baseline and module 4 or 7, including paired samples t tests.

| | Participants, n | Module 1 (baseline), mean (SD) | Comparison level, mean (SD) | Paired difference, mean (SD) | P value | Effect size |
|--|-------------------|--------------------------------|-----------------------------|------------------------------|-----------|-------------|
| Modules 1-4 | 1124 | 14.0 (7.4) | 11.8 (7.9) | 2.2 (5.7) | <.001 | 0.38 |
| Modules 1-7 | 473 | 14.1 (7.3) | 10.5 (8.5) | 3.6 (7.0) | <.001 | 0.51 |
| Module 1 to last available (module 4 or 7) | 1124 | 14.0 (7.4) | 11.2 (8.1) | 2.8 (6.5) | <.001 | 0.43 |

^aPHQ-A: Patient Health Questionnaire adapted for Adolescents.

Discussion

Principal Findings

This article is among the first to analyze national implementation data from an evidence-based self-help intervention for adolescent depression. We present data on reach, engagement, and impact among the target age group (12- to 19-year-olds) from the first 7 years of availability, beginning when SPARX was first offered without referral and at no cost to anyone with a New Zealand IP address. Between 2014 and 2021, approximately 2% of the national adolescent population [30] registered for SPARX, with strong uptake by Indigenous Māori. Participants who completed 2 or more PHQ-A assessments showed moderate improvements in depressive symptoms, with effect sizes comparable to face-to-face therapy [31-33] and consistent with findings from the original RCT of SPARX [7]. Despite the RCT being a pragmatic trial with minimal exclusion criteria and limited additional user contact beyond usual practice [7], real-world use of SPARX differed in key ways; users varied in baseline symptom severity, progressed through the program at different paces, and completed the program at significantly lower rates. These differences highlight the complexities of implementation and the need to address real-world barriers to engagement. Two decades of research have shown that evidence-based digital therapies can be both effective and engaging in controlled settings [34,35]. However, implementation in real-world contexts remains a critical challenge. Analysis of implementation data offers important insights for informing improved impact in communities [35-39].

We have demonstrated that it is feasible to shift from the research setting to real-world implementation in a relatively short time period (ie, going from the publication of the original RCT findings in late 2012 to national roll-out in 2014) and to achieve sizeable population reach. The registration numbers demonstrate interest in the program. While many of those who registered did not begin the intervention, this still represents a major increase in access to evidence-based therapy at a national level. Many interventions fail to reach Indigenous and minoritized youth. The data presented here demonstrate interest from Māori young people. Although given the disproportionate burden of distress experienced by Māori [40], ongoing recruitment efforts are indicated for improving equity. Further efforts are also indicated to reach Pacific adolescents, given the uptake reported was low compared to population numbers and reported distress among Pacific youth [41]. Gender minority adolescents, including transgender and gender-questioning youth, form between 1% and 4% of the New Zealand secondary school population [42], with many reporting depressive symptoms and poor access to care [42]. It is pleasing to see this group having comparatively high engagement with SPARX (eg, 207 transgender adolescent registrations) [43].

The retention of effect size from the RCT to unsupported implementation, as observed in individuals who undergo at least two assessments, is a notable finding. The

efficacy of interventions often diminishes when applied in routine practice [44,45]. The use of computerized programs, which automate delivery, can mitigate decreases in treatment fidelity. Extensive meta-analyses and systematic reviews have established that computerized or internet-delivered therapies for depression can be as effective as face-to-face treatments under research conditions [6,46]. The effect sizes reported in this study underscore treatment effectiveness in the real world. However, there are important caveats. First, these are correlational findings that apply to those completing 2 or more assessments. Second, despite effect sizes matching or exceeding the average for psychotherapeutic treatments for adolescent depression [47], mean postintervention scores remained clinically significant (over the cutoff on the depression measure). These findings emphasize the importance of integrating evidence from both controlled studies and real-world implementation research. They also highlight the ongoing need to enhance the effectiveness of treatments for depression [47].

There were important differences in how public registrants used SPARX compared to the advice given on the website and within the program. Less than half of 12- to 19-year-old users ($n=4609$, 37.4%) were in the target group of mild to moderate symptoms of depression. Almost half reported more severe symptoms ($n=5742$, 46.7%) and hence were automatically advised to get more support and then use SPARX alongside that extra help if desired. We do not know if they did this. Usage also diverged widely from the recommended rate of 1 to 2 modules per week, with most users working through the program much more quickly. It is important to note that users may not use internet-based programs as intended by developers, and hence to adjust communications to users or to adjust the programs themselves to fit user behavior if needed. Adaptive, user-centered approaches (ie, where programs are adjusted to fit user behavior and requirements) are common in the development of digital tools and ensure that interventions evolve to meet user behavior rather than rigidly enforcing compliance with established protocols.

Adherence in this study was considerably lower than in the 2012 RCT, where 86% of those randomized to SPARX completed at least module 4 and 60% completed all 7 modules [7]. Reduced adherence is not unusual in the translation of interventions from research to real-world settings [48], as is seen in digital tools for mental health [18,49] and also in other areas, including face-to-face therapy and medication [26,50,51]. For example, 0.5% of MoodGYM users completed a final assessment in the program as implemented, compared with 22.5% of participants in a trial of the same program [52]. Similarly, routinely collected internet traffic data shows that median retention in publicly available mental health apps is less than a quarter of that reported in trials [18]. Baumeister et al [53] propose that retention in digital self-help apps and programs should be considered in the context of their low barriers to entry. In contrast to the complexities of accessing face-to-face therapies, which may require considerable effort to access, web-based self-help tools can often be accessed without a

referral or an appointment, at any time, often within minutes and at no or low cost. Users may explore multiple tools before selecting one, and some may be “just looking” without the level of concern or motivation involved in getting to a clinical service [53].

Limited retention may be a shortcoming of digital tools, but alternatively, brief engagement might be all that some users need at the time. For example, those who complete only the first module of SPARX still receive key psychoeducation and may benefit from understanding that they are not alone, that there are ways to improve mental health, and that further help is available through the program or other sources. Relatedly, there is evidence of benefits of very brief psychotherapeutic input, where single-session therapies can be helpful [54]. Nevertheless, engagement rates reported here are disappointing. SPARX has not been designed or evaluated as a single-session intervention.

Some limitations in engagement are likely to reflect logistical challenges. For example, users who only had access to a mobile device or who had slow internet speeds would not have been able to begin SPARX in the first years. Second, while the therapeutic content of SPARX had been carefully evaluated, there were opportunities for an improved computer interface and human-computer interaction, for example, in making movement of characters within the game easier and having increased save points within the game. Further, the presentation of SPARX as “a game” may have increased appeal for some adolescents by providing a non-threatening and engaging approach [55]; however, users accustomed to high-budget, rapidly evolving commercial games may have been disappointed [56,57]. These challenges highlight the importance of ongoing technological updates, regular user experience reviews, and ongoing attention to communications about digital tools to target users. An updated version, SPARX 2.0, with enhanced graphics and gameplay and an updated website, was launched in 2023, and data will be reported in future analyses. Further analyses of SPARX onboarding and user experience are underway. Blended care or guided approaches, where iCBT is provided alongside face-to-face therapy or with a therapist or e-coach input by email, text, or telephone support, typically (although not always) yields improved retention in comparison to pure self-help [58]. However, these options also bring increased costs and may reduce appeal for those who want anonymous help or do not want to talk to professionals, an important consideration given so many adolescents with depressive symptoms do not seek professional help [5].

There are important limitations in this study. In total, 7 years of data have been presented. However, this is an observational study: the data are within subject; as such, there is no comparison group. Importantly, the results are correlational; findings may be confounded by spontaneous improvements in PHQ-A scores. Further, it is possible that the participants who were particularly motivated were more likely to both improve and to complete a higher number of modules of SPARX. These findings should, therefore, be

considered alongside those from experimental studies with control groups. There is also no follow-up of those who did not engage, and there is only self-reported data pertaining to a single screening measure. Adolescents who completed the PHQ-A on the SPARX website and then immediately began SPARX would have completed the measure twice within a short time, potentially affecting their responses. While the authors include the co-developers of SPARX or those directly involved in its dissemination, the study plans and results have been reviewed by advisory groups. Implementation issues arose that were specific to this time period and this particular intervention; hence, caution should be exercised in considering implications for other settings. At the same time, there are few studies of this nature, and the findings highlight valuable opportunities for improving the real-world impact of digital interventions.

We have shown that it is possible to roll out iCBT interventions nationally for adolescent depression and significantly increase access to evidence-based therapies in the population. However, this requires ongoing efforts to optimize impact. Reach can be supported by ongoing promotion to users and stakeholders via advertising, training, relationships with providers, and local champions [38]. Improving engagement also requires continued attention. There are many opportunities here, including the ethical use of artificial intelligence. There are examples of effective or promising approaches in the use of single-session interventions [54,59]; the use of brief, just-in-time “micro interventions” [53]; increased use of social or automated support including chatbots, chatrooms, artificial intelligence, and text support [38]; enhanced personalization [49] and cultural responsiveness [38]; developments in telepresence and gamification [60]; increased use of persuasive design [61]; strong co-design, including increased building of digital tools to match how young people use the internet for their own well-being [62]; increased use of promotions, marketing, and champions [38]; and increased integration as part of pathways to care and mental health ecosystems [63]. Rigorously testing these innovations in research settings *and* analyzing and reporting implementation data will be important for rapid and ethical development in the field and to assist in improving mental health outcomes in communities.

Conclusions

Given the barriers to mental health treatment for young people, free and private access to evidence-based digital therapy is essential. Programs that can be made freely available to large numbers of users around the clock are critical components of a comprehensive contemporary mental health system. To optimize the impact of these tools, implementation data should be routinely reported, and ongoing promotion, updates, and development should be prioritized. We propose that providers of evidence-based digital tools, such as iCBT, should routinely report implementation data, and not trial data alone, so that the sector can understand and optimize the health impacts of digital mental health interventions in the real world.

Acknowledgments

We would like to thank the young people and others who have used SPARX (Smart, Positive, Active, Realistic, X-factor thoughts) and the New Zealand Ministry of Health for funding the nation-wide delivery of SPARX, the staff at the National Institute for Health Innovation (NIHI) at the University of Auckland for implementing this over more than 7 years and the stakeholder groups and community members who have worked so hard to increase access to psychological therapy. A particular thanks to those who have worked for many hours on this program, including Arran Culver, Karen Carter, Dianne Wood, and VP. We would like to thank all the adolescent participants who have used the SPARX program and those who have supported them. We would also like to thank Cure Kids who have provided funding for SM and KS.

Conflicts of Interest

The authors declare the following conflicts or potential conflicts of interest with respect to the research, authorship, and publication of this article: the intellectual property for SPARX (Smart, Positive, Active, Realistic, X-factor thoughts) is held by UniServices at the University of Auckland. Any proceeds from licensing or selling SPARX outside of New Zealand will be shared in part with UniServices, the Department of Psychological Medicine at the University of Auckland and the codevelopers: SM, KS, ML, MS, and TF. The National Institute for Health Innovation (NIHI) at the University of Auckland is funded by the government in a not-for-profit contract to provide access to SPARX in New Zealand. CB, VP, TF, KS, and SM are have been or are employed or contracted by NIHI. CB reports institutional funding for grants from the Wellcome Trust, Health Research Council of New Zealand, Education New Zealand, New Zealand Ministry of Foreign Affairs and Trade, New Zealand Ministry of Health, Health New Zealand, CureKids, National Institutes of Health (NIH) and the University of Auckland. There was no payment for the preparation of this paper.

References

1. Clayborne ZM, Varin M, Colman I. Systematic review and meta-analysis: adolescent depression and long-term psychosocial outcomes. *J Am Acad Child Adolesc Psychiatry*. Jan 2019;58(1):72-79. [doi: [10.1016/j.jaac.2018.07.896](https://doi.org/10.1016/j.jaac.2018.07.896)] [Medline: [30577941](https://pubmed.ncbi.nlm.nih.gov/30577941/)]
2. Shorey S, Ng ED, Wong CHJ. Global prevalence of depression and elevated depressive symptoms among adolescents: a systematic review and meta-analysis. *Br J Clin Psychol*. Jun 2022;61(2):287-305. [doi: [10.1111/bjc.12333](https://doi.org/10.1111/bjc.12333)] [Medline: [34569066](https://pubmed.ncbi.nlm.nih.gov/34569066/)]
3. Sutcliffe K, Ball J, Clark TC, et al. Rapid and unequal decline in adolescent mental health and well-being 2012-2019: findings from New Zealand cross-sectional surveys. *Aust N Z J Psychiatry*. Feb 2023;57(2):264-282. [doi: [10.1177/00048674221138503](https://doi.org/10.1177/00048674221138503)] [Medline: [36453262](https://pubmed.ncbi.nlm.nih.gov/36453262/)]
4. Depression in Children and Young People: Identification and Management NICE Guideline. National Institute for Health and Care Excellence; 2019.
5. Radez J, Reardon T, Creswell C, Lawrence PJ, Evdoka-Burton G, Waite P. Why do children and adolescents (not) seek and access professional help for their mental health problems? A systematic review of quantitative and qualitative studies. *Eur Child Adolesc Psychiatry*. Feb 2021;30(2):183-211. [doi: [10.1007/s00787-019-01469-4](https://doi.org/10.1007/s00787-019-01469-4)] [Medline: [31965309](https://pubmed.ncbi.nlm.nih.gov/31965309/)]
6. Karyotaki E, Efthimiou O, Miguel C, et al. Internet-based cognitive behavioral therapy for depression. *JAMA Psychiatry*. Apr 1, 2021;78(4):361. [doi: [10.1001/jamapsychiatry.2020.4364](https://doi.org/10.1001/jamapsychiatry.2020.4364)]
7. Merry SN, Stasiak K, Shepherd M, Frampton C, Fleming T, Lucassen MFG. The effectiveness of SPARX, a computerised self help intervention for adolescents seeking help for depression: randomised controlled non-inferiority trial. *Br Med J*. Apr 18, 2012;344:e2598. [doi: [10.1136/bmj.e2598](https://doi.org/10.1136/bmj.e2598)] [Medline: [22517917](https://pubmed.ncbi.nlm.nih.gov/22517917/)]
8. Shepherd M. An Investigation into the Design, Applicability and Evaluation of a Computerised Cognitive Behavioural Therapy Programme-SPARX for Māori Young People Experiencing Mild to Moderate Depression. The University of Auckland; 2011.
9. Fleming T, Dixon R, Frampton C, Merry S. A pragmatic randomized controlled trial of computerized CBT (SPARX) for symptoms of depression among adolescents excluded from mainstream education. *Behav Cogn Psychother*. Oct 2012;40(5):529-541. [doi: [10.1017/S1352465811000695](https://doi.org/10.1017/S1352465811000695)] [Medline: [22137185](https://pubmed.ncbi.nlm.nih.gov/22137185/)]
10. Lucassen MFG, Merry SN, Hatcher S, Frampton CMA. Rainbow SPARX: a novel approach to addressing depression in sexual minority youth. *Cogn Behav Pract*. May 2015;22(2):203-216. [doi: [10.1016/j.cbpra.2013.12.008](https://doi.org/10.1016/j.cbpra.2013.12.008)]
11. Shepherd M, Merry S, Lambie I, Thompson A. Indigenous adolescents' perception of an eMental health program (SPARX): exploratory qualitative assessment. *JMIR Serious Games*. Jul 5, 2018;6(3):e13. [doi: [10.2196/games.8752](https://doi.org/10.2196/games.8752)] [Medline: [29980495](https://pubmed.ncbi.nlm.nih.gov/29980495/)]
12. Lucassen MFG, Hatcher S, Fleming T, Stasiak K, Shepherd MJ, Merry SN. A qualitative study of sexual minority young people's experiences of computerised therapy for depression. *Australas Psychiatry*. Jun 2015;23(3):268-273. [doi: [10.1177/1039856215579542](https://doi.org/10.1177/1039856215579542)] [Medline: [25881962](https://pubmed.ncbi.nlm.nih.gov/25881962/)]

13. Fleming T, Lucassen M, Stasiak K, Shepherd M, Merry S. The impact and utility of computerised therapy for educationally alienated teenagers: the views of adolescents who participated in an alternative education-based trial. *Clin Psychol (Aust Psychol Soc)*. Jul 1, 2016;20(2):94-102. [doi: [10.1111/cp.12052](https://doi.org/10.1111/cp.12052)]
14. Poppelaars M, Tak YR, Lichtwarck-Aschoff A, et al. A randomized controlled trial comparing two cognitive-behavioral programs for adolescent girls with subclinical depression: A school-based program (Op Volle Kracht) and a computerized program (SPARX). *Behav Res Ther*. May 2016;80:33-42. [doi: [10.1016/j.brat.2016.03.005](https://doi.org/10.1016/j.brat.2016.03.005)] [Medline: [27019280](https://pubmed.ncbi.nlm.nih.gov/27019280/)]
15. Fleming T, Gillham B, Bavin LM, et al. SPARX-R computerized therapy among adolescents in youth offenders' program: step-wise cohort study. *Internet Interv*. Dec 2019;18:100287. [doi: [10.1016/j.invent.2019.100287](https://doi.org/10.1016/j.invent.2019.100287)] [Medline: [31890634](https://pubmed.ncbi.nlm.nih.gov/31890634/)]
16. Perry Y, Werner-Seidler A, Calcar A, et al. Preventing depression in final year secondary students: school-based randomized controlled trial. *J Med Internet Res*. Nov 2, 2017;19(11):e369. [doi: [10.2196/jmir.8241](https://doi.org/10.2196/jmir.8241)] [Medline: [29097357](https://pubmed.ncbi.nlm.nih.gov/29097357/)]
17. Fleming T, Bavin L, Lucassen M, Stasiak K, Hopkins S, Merry S. Beyond the trial: systematic review of real-world uptake and engagement with digital self-help interventions for depression, low mood, or anxiety. *J Med Internet Res*. Jun 6, 2018;20(6):e199. [doi: [10.2196/jmir.9275](https://doi.org/10.2196/jmir.9275)] [Medline: [29875089](https://pubmed.ncbi.nlm.nih.gov/29875089/)]
18. Baumeister A, Muench F, Edan S, Kane JM. Objective user engagement with mental health apps: systematic search and panel-based usage analysis. *J Med Internet Res*. Sep 25, 2019;21(9):e14567. [doi: [10.2196/14567](https://doi.org/10.2196/14567)] [Medline: [31573916](https://pubmed.ncbi.nlm.nih.gov/31573916/)]
19. O'Brien D, Harvey K, Howse J, Reardon T, Creswell C. Barriers to managing child and adolescent mental health problems: a systematic review of primary care practitioners' perceptions. *Br J Gen Pract*. Oct 2016;66(651):e693-707. [doi: [10.3399/bjgp16X687061](https://doi.org/10.3399/bjgp16X687061)] [Medline: [27621291](https://pubmed.ncbi.nlm.nih.gov/27621291/)]
20. Rasmussen EE, Shannon KL, Pitchford B. Adolescents' disclosure of mental illness to parents: preferences and barriers. *Health Commun*. Mar 2022;37(3):346-355. [doi: [10.1080/10410236.2020.1839201](https://doi.org/10.1080/10410236.2020.1839201)] [Medline: [33106039](https://pubmed.ncbi.nlm.nih.gov/33106039/)]
21. Roulston CA, Ahuvia I, Chen S, Fassler J, Fox K, Schleider JL. "My family won't let me." Adolescent-reported barriers to accessing mental health care. *J Res Adolesc*. Mar 2025;35(1):e70013. [doi: [10.1111/jora.70013](https://doi.org/10.1111/jora.70013)] [Medline: [40017261](https://pubmed.ncbi.nlm.nih.gov/40017261/)]
22. Peiris-John R, Ball J, Clark T, Fleming T, and the Adolescent Health Research Group. Youth Mental Health Needs and Opportunities: Leveraging 25 Years of Research from the Youth2000 Survey Series. The University of Auckland and Victoria University of Wellington; 2024.
23. Kho ME, Duffett M, Willison DJ, Cook DJ, Brouwers MC. Written informed consent and selection bias in observational studies using medical records: systematic review. *Br Med J*. Mar 12, 2009;338:b866. [doi: [10.1136/bmj.b866](https://doi.org/10.1136/bmj.b866)] [Medline: [19282440](https://pubmed.ncbi.nlm.nih.gov/19282440/)]
24. National Ethics Advisory Committee. National Ethical Standards for Health and Disability Research and Quality Improvement. Ministry of Health; 2019.
25. Health Information Standards Organisation (HISO), Ministry of Health - Manatū Hauora. HISO 10064:2017 Health Information Governance Guidelines. Ministry of Health; 2017.
26. Vandembroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Int J Surg*. Dec 2014;12(12):1500-1524. [doi: [10.1016/j.ijsu.2014.07.014](https://doi.org/10.1016/j.ijsu.2014.07.014)] [Medline: [25046751](https://pubmed.ncbi.nlm.nih.gov/25046751/)]
27. Levis B, Benedetti A, Thombs BD, DEPRESSion Screening Data (DEPRESSD) Collaboration. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. *Br Med J*. Apr 9, 2019;365:11476. [doi: [10.1136/bmj.11476](https://doi.org/10.1136/bmj.11476)] [Medline: [30967483](https://pubmed.ncbi.nlm.nih.gov/30967483/)]
28. Lumley T, Diehr P, Emerson S, Chen L. The importance of the normality assumption in large public health data sets. *Annu Rev Public Health*. 2002;23:151-169. [doi: [10.1146/annurev.publhealth.23.100901.140546](https://doi.org/10.1146/annurev.publhealth.23.100901.140546)] [Medline: [11910059](https://pubmed.ncbi.nlm.nih.gov/11910059/)]
29. Yao ES, Bullen P, Meissel K, Tiatia J, Fleming T, Clark TC. Effects of ethnic classification on substantive findings in adolescent mental health outcomes. *J Youth Adolesc*. Aug 2022;51(8):1581-1596. [doi: [10.1007/s10964-022-01612-6](https://doi.org/10.1007/s10964-022-01612-6)] [Medline: [35438431](https://pubmed.ncbi.nlm.nih.gov/35438431/)]
30. National population estimates: at 30 june 2022. Statistics New Zealand (Stats NZ). URL: <https://www.stats.govt.nz/information-releases/national-population-estimates-at-30-june-2022/> [Accessed 2024-06-30]
31. Klein JB, Jacobs RH, Reinecke MA. Cognitive-behavioral therapy for adolescent depression: a meta-analytic investigation of changes in effect-size estimates. *J Am Acad Child Adolesc Psychiatry*. Nov 2007;46(11):1403-1413. [doi: [10.1097/chi.0b013e3180592aaa](https://doi.org/10.1097/chi.0b013e3180592aaa)] [Medline: [18049290](https://pubmed.ncbi.nlm.nih.gov/18049290/)]
32. Wuthrich VM, Zagic D, Dickson SJ, et al. Effectiveness of psychotherapy for internalising symptoms in children and adolescents when delivered in routine settings: a systematic review and meta-analysis. *Clin Child Fam Psychol Rev*. Sep 2023;26(3):824-848. [doi: [10.1007/s10567-023-00433-8](https://doi.org/10.1007/s10567-023-00433-8)] [Medline: [37059918](https://pubmed.ncbi.nlm.nih.gov/37059918/)]
33. Kolovos S, van Tulder MW, Cuijpers P, et al. The effect of treatment as usual on major depressive disorder: a meta-analysis. *J Affect Disord*. Mar 1, 2017;210:72-81. [doi: [10.1016/j.jad.2016.12.013](https://doi.org/10.1016/j.jad.2016.12.013)] [Medline: [28013125](https://pubmed.ncbi.nlm.nih.gov/28013125/)]

34. Baños RM, Herrero R, Vara MD. What is the current and future status of digital mental health interventions? *Span J Psychol*. Feb 2, 2022;25:e5. [doi: [10.1017/SJP.2022.2](https://doi.org/10.1017/SJP.2022.2)] [Medline: [35105398](https://pubmed.ncbi.nlm.nih.gov/35105398/)]
35. Mohr DC, Lyon AR, Lattie EG, Reddy M, Schueller SM. Accelerating digital mental health research from early design and creation to successful implementation and sustainment. *J Med Internet Res*. May 10, 2017;19(5):e153. [doi: [10.2196/jmir.7725](https://doi.org/10.2196/jmir.7725)] [Medline: [28490417](https://pubmed.ncbi.nlm.nih.gov/28490417/)]
36. Burger F, Neerinx MA, Brinkman WP. Technological state of the art of electronic mental health interventions for major depressive disorder: systematic literature review. *J Med Internet Res*. Jan 20, 2020;22(1):e12599. [doi: [10.2196/12599](https://doi.org/10.2196/12599)] [Medline: [31958063](https://pubmed.ncbi.nlm.nih.gov/31958063/)]
37. Mohr DC, Azocar F, Bertagnolli A, et al. Banbury forum consensus statement on the path forward for digital mental health treatment. *Psychiatr Serv*. Jun 2021;72(6):677-683. [doi: [10.1176/appi.ps.202000561](https://doi.org/10.1176/appi.ps.202000561)] [Medline: [33467872](https://pubmed.ncbi.nlm.nih.gov/33467872/)]
38. Fleming T, Dewhirst M, Haenga-O'Brien A, et al. Digital Tools for Mental Health and Wellbeing: Opportunities & Impact Findings from the Literature and Community Research. Te Hīringa Hauora | Health Promotion Agency; 2021.
39. Meyerhoff J, Kornfield R, Lattie EG, et al. From formative design to service-ready therapeutic: a pragmatic approach to designing digital mental health interventions across domains. *Internet Interv*. Dec 2023;34:100677. [doi: [10.1016/j.invent.2023.100677](https://doi.org/10.1016/j.invent.2023.100677)] [Medline: [37808416](https://pubmed.ncbi.nlm.nih.gov/37808416/)]
40. Clark TC, Ball J, Fenaughty J, et al. Indigenous adolescent health in Aotearoa New Zealand: trends, policy and advancing equity for rangatahi Maori, 2001-2019. *Lancet Reg Health West Pac*. Nov 2022;28:100554. [doi: [10.1016/j.lanwpc.2022.100554](https://doi.org/10.1016/j.lanwpc.2022.100554)] [Medline: [35996697](https://pubmed.ncbi.nlm.nih.gov/35996697/)]
41. Sutcliffe K, Wilson M, Clark TC, Crengle S, Fleming TT. Distinct profiles of mental health need and high need overall among New Zealand adolescents - cluster analysis of population survey data. *Aust N Z J Psychiatry*. Aug 2024;58(8):678-692. [doi: [10.1177/00048674241243262](https://doi.org/10.1177/00048674241243262)] [Medline: [38600641](https://pubmed.ncbi.nlm.nih.gov/38600641/)]
42. Clark TC, Lucassen MFG, Bullen P, et al. The health and well-being of transgender high school students: results from the New Zealand adolescent health survey (Youth'12). *J Adolesc Health*. Jul 2014;55(1):93-99. [doi: [10.1016/j.jadohealth.2013.11.008](https://doi.org/10.1016/j.jadohealth.2013.11.008)] [Medline: [24438852](https://pubmed.ncbi.nlm.nih.gov/24438852/)]
43. Lucassen MF, Stasiak K, Fleming T, et al. Computerized cognitive behavioural therapy for gender minority adolescents: analysis of the real-world implementation of SPARX in New Zealand. *Aust N Z J Psychiatry*. Sep 2021;55(9):874-882. [doi: [10.1177/0004867420976846](https://doi.org/10.1177/0004867420976846)] [Medline: [33287554](https://pubmed.ncbi.nlm.nih.gov/33287554/)]
44. Breitenstein SM, Gross D, Garvey CA, Hill C, Fogg L, Resnick B. Implementation fidelity in community-based interventions. *Res Nurs Health*. Apr 2010;33(2):164-173. [doi: [10.1002/nur.20373](https://doi.org/10.1002/nur.20373)] [Medline: [20198637](https://pubmed.ncbi.nlm.nih.gov/20198637/)]
45. Ginsburg LR, Hoben M, Easterbrook A, Anderson RA, Estabrooks CA, Norton PG. Fidelity is not easy! Challenges and guidelines for assessing fidelity in complex interventions. *Trials*. May 29, 2021;22(1):372. [doi: [10.1186/s13063-021-05322-5](https://doi.org/10.1186/s13063-021-05322-5)] [Medline: [34051830](https://pubmed.ncbi.nlm.nih.gov/34051830/)]
46. Mamukashvili-Delau M, Koburger N, Dietrich S, Rummel-Kluge C. Long-term efficacy of internet-based cognitive behavioral therapy self-help programs for adults with depression: systematic review and meta-analysis of randomized controlled trials. *JMIR Ment Health*. Aug 22, 2023;10:e46925. [doi: [10.2196/46925](https://doi.org/10.2196/46925)] [Medline: [37606990](https://pubmed.ncbi.nlm.nih.gov/37606990/)]
47. Eckshtain D, Kuppens S, Ugueto A, et al. Meta-analysis: 13-year follow-up of psychotherapy effects on youth depression. *J Am Acad Child Adolesc Psychiatry*. Jan 2020;59(1):45-63. [doi: [10.1016/j.jaac.2019.04.002](https://doi.org/10.1016/j.jaac.2019.04.002)] [Medline: [31004739](https://pubmed.ncbi.nlm.nih.gov/31004739/)]
48. NICE Real-World Evidence Framework Corporate Document [ECD9]. National Institute of Health and Care Excellence; 2022.
49. Lipschitz JM, Pike CK, Hogan TP, Murphy SA, Burdick KE. The engagement problem: a review of engagement with digital mental health interventions and recommendations for a path forward. *Curr Treat Options Psychiatry*. Sep 2023;10(3):119-135. [doi: [10.1007/s40501-023-00297-3](https://doi.org/10.1007/s40501-023-00297-3)] [Medline: [38390026](https://pubmed.ncbi.nlm.nih.gov/38390026/)]
50. Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. *Nat Rev Drug Discov*. May 2023;22(5):387-409. [doi: [10.1038/s41573-023-00670-0](https://doi.org/10.1038/s41573-023-00670-0)] [Medline: [36973491](https://pubmed.ncbi.nlm.nih.gov/36973491/)]
51. Unni EJ, Gupta S, Sternbach N. Reasons for non-adherence with antidepressants using the Medication Adherence Reasons Scale in five European countries and United States. *J Affect Disord*. Jan 1, 2024;344:446-450. [doi: [10.1016/j.jad.2023.10.010](https://doi.org/10.1016/j.jad.2023.10.010)] [Medline: [37832739](https://pubmed.ncbi.nlm.nih.gov/37832739/)]
52. Christensen H, Griffiths KM, Jorm AF. Delivering interventions for depression by using the internet: randomised controlled trial. *Br Med J*. Jan 31, 2004;328(7434):265. [doi: [10.1136/bmj.37945.566632.EE](https://doi.org/10.1136/bmj.37945.566632.EE)] [Medline: [14742346](https://pubmed.ncbi.nlm.nih.gov/14742346/)]
53. Baumel A, Fleming T, Schueller SM. Digital micro interventions for behavioral and mental health gains: core components and conceptualization of digital micro intervention care. *J Med Internet Res*. Oct 29, 2020;22(10):e20631. [doi: [10.2196/20631](https://doi.org/10.2196/20631)] [Medline: [33118946](https://pubmed.ncbi.nlm.nih.gov/33118946/)]

54. Schleider JL, Weisz JR. Little treatments, promising effects? Meta-analysis of single-session interventions for youth psychiatric problems. *J Am Acad Child Adolesc Psychiatry*. Feb 2017;56(2):107-115. [doi: [10.1016/j.jaac.2016.11.007](https://doi.org/10.1016/j.jaac.2016.11.007)] [Medline: [28117056](https://pubmed.ncbi.nlm.nih.gov/28117056/)]
55. Fleming T, Bavin L, Stasiak K, et al. Serious games and gamification for mental health: current status and promising directions. *Front Psychiatry*. 2016;7:215. [doi: [10.3389/fpsy.2016.00215](https://doi.org/10.3389/fpsy.2016.00215)] [Medline: [28119636](https://pubmed.ncbi.nlm.nih.gov/28119636/)]
56. Fleming T, Lucassen M, Stasiak K, Sutcliffe K, Merry S. Technology matters: SPARX - computerised cognitive behavioural therapy for adolescent depression in a game format. *Child Adolesc Ment Health*. Feb 2021;26(1):92-94. [doi: [10.1111/camh.12444](https://doi.org/10.1111/camh.12444)] [Medline: [33393723](https://pubmed.ncbi.nlm.nih.gov/33393723/)]
57. Fleming T, Merry S, Stasiak K, et al. The importance of user segmentation for designing digital therapy for adolescent mental health: findings from scoping processes. *JMIR Ment Health*. May 8, 2019;6(5):e12656. [doi: [10.2196/12656](https://doi.org/10.2196/12656)] [Medline: [31066705](https://pubmed.ncbi.nlm.nih.gov/31066705/)]
58. Krieger T, Bur OT, Weber L, et al. Human contact in internet-based interventions for depression: a pre-registered replication and meta-analysis of randomized trials. *Internet Interv*. Apr 2023;32:100617. [doi: [10.1016/j.invent.2023.100617](https://doi.org/10.1016/j.invent.2023.100617)] [Medline: [37273939](https://pubmed.ncbi.nlm.nih.gov/37273939/)]
59. Osborn TL, Rodriguez M, Wasil AR, et al. Single-session digital intervention for adolescent depression, anxiety, and well-being: outcomes of a randomized controlled trial with Kenyan adolescents. *J Consult Clin Psychol*. Jul 2020;88(7):657-668. [doi: [10.1037/ccp0000505](https://doi.org/10.1037/ccp0000505)] [Medline: [32391709](https://pubmed.ncbi.nlm.nih.gov/32391709/)]
60. Fleming T, Poppelaars M, Thabrew H. The role of gamification in digital mental health. *World Psychiatry*. Feb 2023;22(1):46-47. [doi: [10.1002/wps.21041](https://doi.org/10.1002/wps.21041)] [Medline: [36640378](https://pubmed.ncbi.nlm.nih.gov/36640378/)]
61. Alqahtani F, Al Khalifah G, Oyebode O, Orji R. Apps for mental health: an evaluation of behavior change strategies and recommendations for future development. *Front Artif Intell*. 2019;2:30. [doi: [10.3389/frai.2019.00030](https://doi.org/10.3389/frai.2019.00030)] [Medline: [33733119](https://pubmed.ncbi.nlm.nih.gov/33733119/)]
62. Thabrew H, Fleming T, Hetrick S, Merry S. Co-design of eHealth interventions with children and young people. *Front Psychiatry*. 2018;9:481. [doi: [10.3389/fpsy.2018.00481](https://doi.org/10.3389/fpsy.2018.00481)] [Medline: [30405450](https://pubmed.ncbi.nlm.nih.gov/30405450/)]
63. Merry SN, Cargo T, Christie G, et al. Debate: supporting the mental health of school students in the COVID-19 pandemic in New Zealand - a digital ecosystem approach. *Child Adolesc Ment Health*. Nov 2020;25(4):267-269. [doi: [10.1111/camh.12429](https://doi.org/10.1111/camh.12429)] [Medline: [33025729](https://pubmed.ncbi.nlm.nih.gov/33025729/)]

Abbreviations

CBT: cognitive behavioral therapy

iCBT: internet-based cognitive behavioral therapy

IP: Internet Protocol

PHQ-A: Patient Health Questionnaire adapted for Adolescents

RCT: randomized controlled trial

SPARX: Smart, Positive, Active, Realistic, X-factor thoughts

STROBE: Strengthening the Reporting of Observational Studies in Epidemiology

Edited by Taiane de Azevedo Cardoso; peer-reviewed by Arka Ghosh, Debayan Podder; submitted 03.09.2024; final revised version received 11.04.2025; accepted 15.04.2025; published 25.08.2025

Please cite as:

Fleming T, Lucassen M, Frampton C, Parag V, Bullen C, Merry S, Shepherd M, Stasiak K

Nationwide Implementation of Unguided Cognitive Behavioral Therapy for Adolescent Depression: Observational Study of SPARX

J Med Internet Res 2025;27:e66047

URL: <https://www.jmir.org/2025/1/e66047>

doi: [10.2196/66047](https://doi.org/10.2196/66047)

© Terry Fleming, Mathijs Lucassen, Chris Frampton, Varsha Parag, Chris Bullen, Sally Merry, Matthew Shepherd, Karolina Stasiak. Originally published in the Journal of Medical Internet Research (<https://www.jmir.org>), 25.08.2025. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research (ISSN 1438-8871), is properly cited. The complete bibliographic information, a link to the original publication on <https://www.jmir.org>, as well as this copyright and license information must be included.